Pharma Mar (PHMMF) Stock Price, News & Analysis

Company Overview

Pharma Mar, S.A. is a Spanish biopharmaceutical company focused on discovering, developing and commercializing medicines derived from marine organisms. The company specializes primarily in oncology, using compounds identified from marine invertebrates and microorganisms as the basis for treatments targeting difficult-to-treat cancers.

Its principal products include Yondelis (trabectedin), which is used in certain markets to treat advanced soft-tissue sarcoma and relapsed ovarian cancer, and Zepzelca (lurbinectedin), an anticancer therapy for metastatic small-cell lung cancer that received accelerated approval in the United States. Pharma Mar also maintains a pipeline of investigational compounds, including plitidepsin, and has conducted research in other therapeutic areas through its RNA-interference platform.

Headquartered in Spain, Pharma Mar serves international markets through its own commercial operations and licensing or distribution partnerships. The company was established in 1986 as part of the Zeltia group and later adopted the Pharma Mar name as its primary corporate identity. José María Fernández Sousa-Faro has served as the company’s chairman and chief executive officer.

Key Stats

• Today's Range: $94.60 to $94.60
• 50-Day Range: $79.49 to $97.36
• 52-Week Range: $77.41 to $110.40
• Volume: N/A
• Average Volume: 15 shs
• Market Capitalization: $1.70 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Pharma Mar Stock Analysis - MarketRank™

Pharma Mar scored higher than 6% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Pharma Mar has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Pharma Mar has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Pharma Mar are expected to grow in the coming year, from ($1.04) to $2.14 per share.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

0.05% of the float of Pharma Mar has been sold short.

Short Interest Ratio / Days to Cover

Pharma Mar has a short interest ratio ("days to cover") of 241.17, which indicates bearish sentiment.

Change versus previous month

Short interest in Pharma Mar has recently increased by 9,136.17%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Pharma Mar does not currently pay a dividend.

Dividend Growth

Pharma Mar does not have a long track record of dividend growth.

News and Social Media

• Score: 1.0 / 5
• News Sentiment: N/A

News Sentiment

Pharma Mar has a news sentiment score of -0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Pharma Mar this week, compared to 0 articles on an average week.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Pharma Mar insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.88% of the stock of Pharma Mar is held by insiders.

Percentage Held by Institutions

Pharma Mar has minimal institutional ownership at this time.

Company Calendar

• Today: 9/15/2026
• Next Earnings (Estimated): 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: OTCMKTS:PHMMF
• Previous Symbol: NASDAQ:PHMMF
• CIK: N/A
• Web: www.pharmamar.com
• Phone: (491) 846-6000
• Fax: 34-91-846-6001
• Employees: 509
• Year Founded: 1986

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: 0.14
• Current Ratio: 3.02
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $250.42 million
• Price / Sales: 6.80
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 18,000,000
• Free Float: 17,662,000
• Market Cap: $1.70 billion
• Optionable: Not Optionable
• Beta: 0.71